What is true is that Medicago had challenges stabilizing the vaccine for mass production, as I understand it. Further investments would have been needed to be able to get it into a position of broad-scale distribution.
Certainly, if it were the only viable option—if it were at a different place—those investments would have been made. I don't think you can ignore the fact that a large number of very successful vaccines were already in wide deployment, so those investments wouldn't have been logical.